

72. Godal HC, Madsen K, Nissen-Meyer R. Thromboembolism in patients with total proconvertin deficiency. A report of two cases. *Acta Med Scand*. 1962;171:325-327.

73. Mariani G, Herrmann FH, Schulman S, et al. Thrombosis in inherited factor VII deficiency. *J Thromb Haemost*. 2003;1:2153-2158.

74. Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. *N Engl J Med*. 1982;307:1191-1195.

75. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. *Br J Haematol*. 1988;69:521-528.

76. Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris MA. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family. *Blood*. 2003;101:3492-3494.

77. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. *Haemophilia*. 2001;7(suppl 1):16-22.

78. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. *Transfusion*. 2002;42:1230-1237.

79. Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. *Transfusion*. 1998;38:102-107.

80. Riggert J, Humpe A, Legler TJ, et al. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination. *Transfusion*. 2001;41:82-86.

81. Llewelyn CA, Hewitt PE, Knight RS. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet*. 2004;363:417-421.

82. Chuansumrit A, Mahaphan W, Pintadit P, et al. Combined factor V and factor VIII deficiency with congenital heart disease: response to plasma and DDAVP infusion. *Southeast Asian J Trop Med Public Health*. 1994;25:217-220.

83. Bauduer F, Guichandut JP, Ducout L. Successful use of fresh frozen plasma and desmopressin for transurethral prostatectomy in a French Basque with combined factors V+VIII deficiency. *J Thromb Haemost*. 2004;2:675-676.

84. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. *Haemophilia*. 1999;5:253-259.

85. Mariani G, Testa MG, Di Paolantonio T, Molskov BR, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. *Vox Sang*. 1999;77:131-136.

86. Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. *Thromb Haemost*. 1978;39:675-682.

87. Cohen LJ, McWilliams NB, Neuberger R, et al. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. *Am J Hematol*. 1995;50:269-276.

88. Bolton-Maggs PH, Wensley RT, Kernoff PB, et al. Production and therapeutic use of a factor XI concentrate from plasma. *Thromb Haemost*. 1992;67:314-319.

89. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. *Lancet*. 1994;344:748-749.

90. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. *Blood*. 1994;84:1314-1319.

91. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. *Br J Haematol*. 1997;96:293-297.

92. Rodeghiero F, Castaman GC, Di Bona E, Ruggeri M, Dini E. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. *Blut*. 1987;55:45-48.

93. Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. *Thromb Haemost*. 1995;74:622-625.

94. Winkelman L, Sims GE, Haddon ME, et al. A pasteurized concentrate of human plasma factor XIII for therapeutic use. *Thromb Haemost*. 1986;55:402-405.

95. Reynolds TC, Butine M, Visich JE, et al. A randomized, placebo-controlled, double-blind, multi-dose study of the safety and pharmacokinetics of recombinant factor XIII administration in healthy volunteers [abstract]. *Blood*. 2003;102:98b.

96. Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. *Semin Thromb Hemost*. 1996;22:415-418.

97. Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. *Blood*. 2003;101:4783-4788.

## Erratum

In the article by Alberich Jordà et al entitled "The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner," which appeared in the July 15, 2004, issue of *Blood* (Volume 104:526-534), part of Figure 3A was missing. The complete panel 3A is shown below.

